Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
Stock Snapshot
Regeneron(REGN) stock is priced at $755.51, giving the company a market capitalization of 82.92B. It carries a P/E multiple of 18.09 and pays a dividend yield of 46.6%.
On 2026-01-23, Regeneron(REGN) stock moved within a range of $747.37 to $764.89. With shares now at $755.51, the stock is trading +1.1% above its intraday low and -1.2% below the session's peak.
Trading activity shows a volume of 765.3K, compared to an average daily volume of 958.98K.
The stock's 52-week range extends from a low of $476.49 to a high of $821.11.
The stock's 52-week range extends from a low of $476.49 to a high of $821.11.
REGN News
Evercore ISI raised the firm’s price target on Regeneron (REGN) to $875 from $750 and keeps an Outperform rating on the shares. Regeneron is “looking strong wit...
Regeneron Pharmaceuticals (NasdaqGS:REGN) has seen the departure of Dr. Wolfgang Liedtke, its Chair of Neurology. Dr. Liedtke is joining Anavex Life Sciences i...
Shareholders of Regeneron Pharmaceuticals, Inc. (Symbol: REGN) looking to boost their income beyond the stock's 0.5% annualized dividend yield can sell the June...
Analyst ratings
70%
of 30 ratingsMore REGN News
Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium Regeneron’s latest clinical update center...
Morgan Stanley analyst Terence Flynn has maintained their neutral stance on REGN stock, giving a Hold rating on January 14. Claim 50% Off TipRanks Premium Unloc...
Recently, Regeneron Pharmaceuticals’ leadership outlined a plan to prioritize internal research and development over large acquisitions as it approaches key pat...